An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Men

The purpose of this first time in human (FTiH) study is to evaluate the safety, reactogenicity and immunogenicity of several formulations of Respiratory Syncytial Virus (RSV) investigational vaccines in healthy men.

本首次人体（First Time in Human, FTiH）研究旨在评估多款呼吸道合胞病毒（Respiratory Syncytial Virus, RSV）研究性疫苗的多种制剂在健康男性人群中的安全性、反应原性与免疫原性。